**2025-05**

**Pimitespib**​
Pimitespib, an **HSP90 inhibitor**approved in Japan for gastrointestinal cancers, **may overcome resistance to androgen receptor pathway inhibitors (ARPIs)**like enzalutamide and abiraterone in mCRPC. HSP90 stabilizes proteins that drive therapy resistance, including AR, AR-V7, GR, and AKT. In lab studies, pimitespib disrupted these proteins, enhanced ARPI effectiveness, and blocked nuclear signaling pathways fueling cancer growth. In animal models, pimitespib combined with enzalutamide showed strong tumor-shrinking effects without major toxicity.